We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Prexa Pharmaceuticals Obtains $7.0 Million in Series B Financing
News

Prexa Pharmaceuticals Obtains $7.0 Million in Series B Financing

Prexa Pharmaceuticals Obtains $7.0 Million in Series B Financing
News

Prexa Pharmaceuticals Obtains $7.0 Million in Series B Financing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Prexa Pharmaceuticals Obtains $7.0 Million in Series B Financing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Prexa Pharmaceuticals, has announced it has secured $7.0 million in a Series B financing. The round was led by Advent Healthcare Ventures and also included Shire Pharmaceuticals as a new investor.

Proceeds from the financing will allow the company to complete IND-enabling studies through Phase 1b clinical studies for its lead product candidate PRX-12251.

Prexa was co-founded by Advent in 2006, and has previously raised $3.1 million in a Series A equity capital financing. The Company is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter.

By safely enhancing dopamine activity, and to a lesser extent norepinephrine activity, Prexa intends to improve upon the safety and efficacy of current treatments for ADHD, depression and Parkinson's disease.

"We are excited about Shire's participation in this round of financing, and are pleased that they share our confidence in Prexa's unique approach to treating CNS diseases and disorders," said Charles Cohen, Ph.D., Partner at Advent Healthcare Ventures and Chairman and CEO of Prexa.

Cohen continued, "We are targeting indications that we believe have an unmet need and we now have the funding in place, and an experienced management team on board to advance the development of Prexa's lead product candidate."

Many CNS diseases and disorders have been associated with impaired neurotransmission of the serotonin, norepinephrine, and dopamine pathways. However, most pharmacologic treatments aim to enhance only serotonin and/or norepinephrine.

Many patients do not adequately respond to these products, are dissatisfied with their side effects, or feel they respond too slowly. Prexa's lead compound, PRX-12251, is a triple reuptake inhibitor (TRI) that blocks dopamine, norepinephrine and serotonin transporters, with the greatest potency on the dopamine transporter.

"There is a strong body of clinical evidence to suggest that preferentially targeting dopamine, with less potent effects on serotonin and norepinephrine, may provide clinical advantages to treating certain CNS disorders. We believe that agents with this pharmacology offer the potential for improved efficacy and safety in various psychiatric and neurological conditions," said Scott Reines, M.D., Ph.D., Chief Medical Officer of Prexa.

Reines continued, "We are pleased to have the support of Advent and Shire, and expect that our capital efficient structure will allow these funds to take PRX-12251 through Phase 1 clinical studies that include characterization of its pharmacodynamic effects in human brain."

Advertisement